BENTYL
LOE ApproachingNDAORALCAPSULE
Approved
May 1950
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
BENTYL is an oral capsule small-molecule NDA approved in 1950 by AbbVie for an undisclosed indication. The drug's mechanism of action and specific indications are not documented in available data, limiting clinical characterization.
$0.051MPart D
LOE ApproachingMature product approaching loss of exclusivity with minimal recent spending and claim volume, suggesting a small, stable patient base and declining commercial investment.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job postings indicate minimal current hiring for BENTYL roles. Career growth on this product is limited due to its approaching loss of exclusivity and mature market position.
Brand ManagerSales Representative
Worked on BENTYL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.